ZVRAZevra Therapeutics, Inc.

$618M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+71.9% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$3M-135.8% margin

Net Income

-$5M-205.2% margin

EPS (Diluted)

$-1.07

QoQ Revenue Growth

+22.9%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$1M

Stock-Based Comp.

$457,000

Balance Sheet

Total Assets

$11M

Total Liabilities

$78M

Stockholders' Equity

-$66M

Cash & Equivalents

$4M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$1M	+71.9%
Gross Profit	$2M	-$569,000	+515.8%
Operating Income	-$3M	-$4M	+27.1%
Net Income	-$5M	-$6M	+19.6%

ZVRA Q4 2020 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena